Sleep Disorders

Seminars in Neurology

Volumn 23, Issue 3, 2003, Pages 307-314

  Krahn, Lois E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cataplexy; Narcolepsy; Rapid eye movement behavior disorder; Restless legs

Indexed keywords

ADOLESCENT; ADULT; AGED; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; FEMALE; HUMAN; HYPERSOMNIA; MALE; NARCOLEPSY; NIGHT; PARASOMNIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE;

ADJUVANTS, ANESTHESIA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CATAPLEXY; DISORDERS OF EXCESSIVE SOMNOLENCE; ELECTROENCEPHALOGRAPHY; FEMALE; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; POLYSOMNOGRAPHY; REM SLEEP BEHAVIOR DISORDER; RESTLESS LEGS SYNDROME; SLEEP APNEA, OBSTRUCTIVE; SLEEP DISORDERS; SLEEP STAGES; SODIUM OXYBATE;

EID: 0348108321     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-814742     Document Type: Review

References (65)

1. Silber M, Krahn L, Olson E, Pankratz V. Epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2001;24:A98
2. Krahn L, Boeve B, Olson E, Herold D, Silber M. A standardized test for cataplexy. Sleep Med 2000;1:125-130
3. Broughton R, Guberman A, Roberts J. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: a controlled study. Epilepsia 1984;25:423-433
4. Silber M, Krahn L, Olson E, Pankratz V. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002;25:197-202
5. Mignot E, Hayduk R, Black J, Grumet F, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-1020
6. Chervin R, Dillon J, Bassetti C, Ganoczy D, Pituch K. Symptoms of sleep disorders, inattention, and hyperactivity in children. Sleep 1997;20:1185-1192
7. Krahn L, Hansen M, Shepard J. Pseudocataplexy. Psychosomatics 2001;42:356-358
8. Krahn L, Black J, Silber M. Narcolepsy: new understanding of irresistible sleep. Mayo Clin Proc 2001;76:185-194
9. Overeem S, Mignot E, Gert van Dijk J, Lammers G. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105
10. Black J, Krahn L, Silber M. A pilot study of serologic markers of autoimmunity in patients with narcolepsy. Sleep 2001;24: A318-A319
11. Thannickal T, Moore R, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474
12. Nishino S, Ripley B, Overeem S, Lammers G, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy (letter). Lancet 2000;355:39-40
13. Schuld A, Blum W, Pollmacher T. Low CSF hypocretin (orexin) and altered energy metabolism in human narcolepsy. Ann Neurol 2002;51:660-661
14. Mignot E, Lammers G, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562
15. Smart D, Jerman J. The physiology and pharmacology of the orexins. Pharmacol Ther 2002;94:51-61
16. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
17. Scharf M, Lai A, Branigan B, Stover R, Berkowitz D. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998;21:507-514
18. Zyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25:42-49
19. Mitler M, Shafor R, Hajdukovich R, Timms R, Browman C. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986;9:260-264
20. Billiard M, Merle C, Carlander B, Ondze B, Alvarez D, Besset A. Idiopathic hypersomnia. Psychiatry Clin Neurosci 1998;52:125-129
21. Bassetti C, Aldrich M. Idiopathic hypersomnia: a series of 42 patients. Brain 1997;120:1423-1435
22. Kanbayashi T, Inque Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-93
23. Walker R. Long-term health consequences of mild to moderate obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 2001;127:1397-1400
24. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235
25. Young T, Peppard P, Gottlieb D. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239
26. Partinen M. Epidemiology of obstructive sleep apnea syndrome. Curr Opin Pulm Med 1995;1:482-487
27. Rama A, Tekwani S, Kushida C. Sites of obstruction in obstructive sleep apnea. Chest 2002;122:1139-1147
28. Dart R, Gregoire J, Gutterman D, Woolf S. The association of hypertension and secondary cardiovascular disease with sleep-disordered breathing. Chest 2003;123:244-260
29. Bananian S, Lehrman S, Maguire G. Cardiovascular consequences of sleep-related breathing disorders. Heart Dis 2002; 4:296-305
30. Loh N, Dinner D, Foldvary N, Skobieranda F, Yew W. Do patients with obstructive sleep apnea wake up with headaches? Arch Intern Med 1999;159:1765-1768
31. Dodick D, Eross E, Parish J. Clinical, anatomical, and physiologic relationship between sleep and headache. Headache 34:282-292
32. Berry R, Parish J, Hartse K. The use of auto-titrating continuous positive airway pressure for the treatment of adult obstructive sleep apnea: an American Academy of Sleep Medicine review. Sleep 2002;25:148-173
33. Sullivan C, Grunstein R. Continuous positive airway pressure in sleep-disordered breathing. In: Kryger M, Roth T, Dement W, eds. Principles and Practice of Sleep Medicine. 2nd ed. Philadelphia: WB Saunders; 1994;694
34. Clark G, Blumenfeld I, Yoffe N, Peled E, Lavie P. A crossover study comparing the efficiency of continuous positive airway pressure with anterior mandibular positioning devices on patients with obstructive sleep apnea. Chest 1996;109:1477-1483
35. Flemons W. Obstructive sleep apnea. N Engl J Med 2002; 347:498-504
36. Lojander P, Maasilta P, Partinen M, Brander P, Salmi T, Lehtonen H. Nasal-CPAP and conservative management for treatment of obstructive sleep apnea syndrome: a randomized study. Chest 1996;110:114-119
37. Littner M, Kushida C, Hartse K, et al. Practice parameters for the use of laser-assisted uvulopalatoplasty: an update for 2000. Sleep 2001;24:603-619
38. Berry R, Deas M, Light R. Effect of ethanol on the efficacy of nasal continuous positive airway pressure as a treatment for obstructive sleep apnea. Chest 1991;99:339-341
39. Dolly F, Block A. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med 1982;73:239-243
40. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic and genetic characteristics of restless legs syndrome: a study of 133 patients with new standard criteria. Move Disord 1997;12:61-65
41. Chaudhuri K, Appiah-Kubi L, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry 2001;71:143-146
42. Nicolas A, Michaud M, Lavigne G, Montplaisir J. The influence of sex, age and sleep/wake state on characteristics of periodic leg movements in restless legs syndrome patients. J Clin Neurophysiol 1999;110:1168-1174
43. Phillips B, Young T, Finn L, Asher K, Hening W, Purvis C. Epidemiology of restless legs syndrome in adults. Arch Intern Med 2000;160:2137-2141
44. Ohayon M, Roth T. Prevalence of restless legs syndrome and periodic movement disorder in the general population. J Psychosom Res 2002;53:547-554
45. Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau G. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001;69:1266-1270
46. Bonati M, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003;126:1485-1492
47. Winkelmann J, Chertow G, Lazarus J. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996;28:372-378
48. Takaki J, Nishi T, Nangaku M, et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 2003;41:833-839
49. Ruottinen H, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-504
50. Earley C, Allen R, Beard J, Connor J. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000; 62:623-628
51. Allen R, Earley C. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-147
52. Comella C. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002;58:S87-S92
53. Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002;252:185-194
54. Pritchett A, Morrison J, Edwards WD, Schaff H, Connolly H, Espinosa R. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286
55. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579
56. Walters A, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Move Disord 2001;16:1105-1109
57. Davis B, Rajput A, Rajput M, Aul E, Eichhorn G. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000;43:70-75
58. Schenck C, Bundlie S, Ettinger M, Mahowald M. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9:293-308
59. Schenck C, Hurwitz T, Mahowald M. Symposium: normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. Sleep 1993;2:224-231
60. Olson E, Boeve B, Silber M. Rapid eye movement sleep behavior disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339
61. Schenck C, Mahowald M, Kim S, O'Connor K, Hurwitz T. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15:226-235
62. Comella C, Nardine T, Diedrich N, Stebbins G. Sleep-related violence, injuries and REM behavior disorder in Parkinson's disease. Neurology 1998;51:526-529
63. Plazzi G, Corsini R, Provini F, et al. REM behavior disorder in multiple system atrophy. Neurology 1997;48:1094-1097
64. Boeve B, Silber M, Ferman T, Lucas J, Parisi J. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Move Disord 2001;16:622-630
65. Schenck C, Mahowald M. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996;100:333-337